Cardiomyopathy, familial dilated

被引:0
|
作者
Matthew RG Taylor
Elisa Carniel
Luisa Mestroni
机构
[1] University of Colorado Health Sciences Center,University of Colorado Cardiovascular Institute and Adult Medical Genetics Program, Department of Internal Medicine
来源
Orphanet Journal of Rare Diseases | / 1卷
关键词
Genetic Counseling; Cardiac Resynchronization Therapy; Carvedilol; Angiotensin Converting Enzyme Inhibitor; Left Ventricular Assist Device;
D O I
暂无
中图分类号
学科分类号
摘要
Dilated cardiomyopathy (DCM) is a heart muscle disease characterized by ventricular dilatation and impaired systolic function. Patients with DCM suffer from heart failure, arrhythmia, and are at risk of premature death. DCM has a prevalence of one case out of 2500 individuals with an incidence of 7/100,000/year (but may be under diagnosed). In many cases the disease is inherited and is termed familial DCM (FDC). FDC may account for 20–48% of DCM. FDC is principally caused by genetic mutations in FDC genes that encode for cytoskeletal and sarcomeric proteins in the cardiac myocyte. Family history analysis is an important tool for identifying families affected by FDC. Standard criteria for evaluating FDC families have been published and the use of such criteria is increasing. Clinical genetic testing has been developed for some FDC genes and will be increasingly utilized for evaluating FDC families. Through the use of family screening by pedigree analysis and/or genetic testing, it is possible to identify patients at earlier, or even presymptomatic stages of their disease. This presents an opportunity to invoke lifestyle changes and to provide pharmacological therapy earlier in the course of disease. Genetic counseling is used to identify additional asymptomatic family members who are at risk of developing symptoms, allowing for regular screening of these individuals. The management of FDC focuses on limiting the progression of heart failure and controlling arrhythmia, and is based on currently accepted treatment guidelines for DCM. It includes general measures (salt and fluid restriction, treatment of hypertension, limitation of alcohol intake, control of body weight, moderate exercise) and pharmacotherapy. Cardiac resynchronization, implantable cardioverter defibrillators and left ventricular assist devices have progressively expanding usage. Patients with severe heart failure, severe reduction of the functional capacity and depressed left ventricular ejection fraction have a low survival rate and may require heart transplant.
引用
收藏
相关论文
共 50 条
  • [21] CRT for Dilated Cardiomyopathy Time for a Personalized Approach
    Linde, Cecilia
    JACC-CLINICAL ELECTROPHYSIOLOGY, 2024, 10 (07) : 1465 - 1467
  • [22] Distribution of strain patterns in children with dilated cardiomyopathy
    den Boer, Susanna L.
    Sarvaas, Gideon J. du Marchie
    Klitsie, Liselotte M.
    van Iperen, Gabrielle G.
    Tanke, Ronald B.
    Helbing, Willem A.
    Backx, Ad P. C. M.
    Rammeloo, Lukas A. J.
    Dalinghaus, Michiel
    ten Harkel, Arend D. J.
    ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED TECHNIQUES, 2017, 34 (06): : 881 - 887
  • [23] Differential outcome of cardiac resynchronization therapy in ischemic cardiomyopathy and idiopathic dilated cardiomyopathy
    McLeod, Christopher J.
    Shen, Win-Kuang
    Rea, Robert F.
    Friedman, Paul A.
    Hayes, David L.
    Wokhlu, Anita
    Webster, Tracy L.
    Wiste, Heather J.
    Hodge, David O.
    Bradley, David J.
    Hammill, Stephen C.
    Packer, Douglas L.
    Cha, Yong-Mei
    HEART RHYTHM, 2011, 8 (03) : 377 - 382
  • [24] The remarkable effect of ivabradine in two adolescents with dilated cardiomyopathy
    Parsons, Sunaina
    Clark, Andrew L.
    Cleland, John G. F.
    CLINICAL RESEARCH IN CARDIOLOGY, 2014, 103 (10) : 847 - 849
  • [25] Non-ischemic dilated cardiomyopathy and cardiac fibrosis
    Bianca Olivia Cojan-Minzat
    Alexandru Zlibut
    Lucia Agoston-Coldea
    Heart Failure Reviews, 2021, 26 : 1081 - 1101
  • [26] Sex and gender differences in myocarditis and dilated cardiomyopathy: An update
    Fairweather, DeLisa
    Beetler, Danielle J.
    Musigk, Nicolas
    Heidecker, Bettina
    Lyle, Melissa A.
    Cooper, Leslie T.
    Bruno, Katelyn A.
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2023, 10
  • [27] Electrophysiological Effects of Carvedilol Administration in Patients with Dilated Cardiomyopathy
    Emmanuel M. Kanoupakis
    Emmanuel G. Manios
    Hercules E. Mavrakis
    Eleftherios M. Kallergis
    George M. Lyrarakis
    Emmanuel P. Koutalas
    Panos E. Vardas
    Cardiovascular Drugs and Therapy, 2008, 22 : 169 - 176
  • [28] The remarkable effect of ivabradine in two adolescents with dilated cardiomyopathy
    Sunaina Parsons
    Andrew L. Clark
    John G. F. Cleland
    Clinical Research in Cardiology, 2014, 103 : 847 - 849
  • [29] Outcome of patients with dilated cardiomyopathy in a contemporary Swiss population
    Vischer, Annina
    Osswald, Stefan
    Sticherling, Christian
    Schaer, Beat
    ACTA CARDIOLOGICA, 2009, 64 (03) : 347 - 350
  • [30] The natural history of dilated cardiomyopathy: how has it changed?
    Merlo, Marco
    Gentile, Piero
    Naso, Paola
    Sinagra, Gianfranco
    JOURNAL OF CARDIOVASCULAR MEDICINE, 2017, 18 : e161 - e165